Aspirin on CTCs of Advanced Breast and Colorectal Cancer (ACABC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02602938|
Recruitment Status : Unknown
Verified November 2015 by Chao Ni, Zhejiang Provincial People’s Hospital.
Recruitment status was: Recruiting
First Posted : November 11, 2015
Last Update Posted : November 13, 2015
|Condition or disease||Intervention/treatment||Phase|
|Epithelial-Mesenchymal Transition Circulating Tumor Cells||Drug: Aspirin||Phase 2|
- Invasion and metastasis are the main reason of death in metastatic cancer, and abundant evidence find circulating tumor cells(CTCs) take the core position in breast and colorectal cancer metastasis.
- Platelets play multiple role to facilitate the epithelial to mesenchymal transition of tumor cells and protect CTCs to survival in the circulation, which enrolled in the whole process of metastasis.
- Several clinical trials and observational study have validate the primary and secondary prevention effect of aspirin to both breast and colorectal cancer.
- Determine the effect of aspirin on CTC number of metastatic breast and colorectal cancer;
- Determine the effect of aspirin on CTC subtype (epithelial/mesenchymal/mixed type) of metastatic breast and colorectal cancer.
- Adults age from 18-75 years old.
- Patients were diagnosed for metastatic breast or colorectal cancer by pathology.
- Patients who were not currently receiving intravenous chemotherapy , oral administrated with capecitabine was permitted. Concurrent endocrine therapy ( for at least 2 months before enrollment), bisphosphonate therapy, and/or monoclonal targeted therapy were permitted.
- No disease of hemorrhagic tendency or history of non-steroid drug allergy.
- CTCs≥5 / 7.5ml blood
- Aspirin will be administered orally once a day in 28-day cycles.
- The CTC was evaluated every 28 days for 2 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Study Start Date :||November 2015|
|Estimated Primary Completion Date :||November 2016|
|Estimated Study Completion Date :||February 2017|
Take aspirin (100mg) orally once a day for 2 months
Other Name: acetylsalicylic acid
- Intervention completed [ Time Frame: 2 months ]2-months follow-up completed and the CTCs' assessment was evaluated three times by Canpatrol technology, the tumor burden was evaluated by MRI or CT.
- Disease progression [ Time Frame: 2 months ]The tumor burden would be examined by MRI or CT once a month, if we find the cancer progressed and chemotherapy is needed, the patient will be withdraw.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02602938
|Contact: Chao Ni, Doctorfirstname.lastname@example.org|
|Contact: Yun Chen, Doctoremail@example.com|
|Zhejiang provincial people's hospital||Recruiting|
|Hangzhou, Zhejiang, China, 310014|
|Contact: Jinwen Qi +8613758248488 firstname.lastname@example.org|
|Contact: Chao Ni +8613989463951 email@example.com|